RxDoctor Payments Data

Garnelle Florez

Psychiatric/Mental Health · Kearney, NENPI 1912675307

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 77 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$622
  • Alkermes, Inc.$349
  • Otsuka America Pharmaceutical, Inc.$286
  • Teva Pharmaceuticals USA, Inc.$172
  • Axsome Therapeutics, Inc.$76
  • Johnson & Johnson$74
  • plus $142 from 4 others

What the payments were for

  • Food & beverage$1,61094%
  • Education$1116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,721 in reported general payments places this provider in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$5,644
Medicare patients
15
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate18$62,812
VraylarCariprazine Hcl13$18,909
VyvanseLisdexamfetamine Dimesylate13$5,076
Clozapine12$1,302
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,180
Bupropion XlBupropion Hcl35$1,100
Vilazodone Hcl12$715
Sertraline Hcl52$700
Quetiapine Fumarate54$699
Oxcarbazepine12$589
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$560
Amitriptyline Hcl38$516
Duloxetine Hcl29$372
Buspirone Hcl41$364
Gabapentin36$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$74$62,81218 claims
AbbVieVraylar$622$18,90913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →